Calcium channel blockers (versus unexposed)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13875
R54260		 Darcie - Isradipine, 2004 Cesarean late pregnancy prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.91 [0.54;6.78] C 28/39   8/14 36 39
ref
S13969
R54752		 Parazzini - Nifedipine, 1998 Caesarean section 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 0.70 [0.40;1.10] 72/128   77/124 149 128
ref
S13988
R54963		 Magee - Calcium blockers, 1996 Cesarean section at least 1st trimester excluded prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.51 [0.69;3.28] C
excluded (exposition period) 		18/47   21/72 39 47
ref
S13986
R54916		 Wide-Swensson - Isradipine, 1995 Cesarean section 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 1.31 [0.52;3.30] C 14/47   11/45 25 47
ref
Total 3 studies 0.99 [0.56;1.76] 210 214
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Darcie - Isradipine, 2004Darcie - Isradipine, 2004 1.91[0.54; 6.78]363917%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Parazzini - Nifedipine, 1998Parazzini - Nifedipine, 1998 0.70[0.40; 1.10]14912855%ROB confusion: lowROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Wide-Swensson - Isradipine, 1995Wide-Swensson - Isradipine, 1995 1.31[0.52; 3.30]254728%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: lowROB reporting: moderate Total (3 studies) I2 = 32% 0.99[0.56; 1.76]2102140.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.91[0.54; 6.78]3639 -NADarcie - Isradipine, 2004 1 case control studiescase control studies 0 RCTRCT 0.85[0.48; 1.49]17417527%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 Type of controls unexposed, sickunexposed, sick 0.99[0.56; 1.76]21021432%NADarcie - Isradipine, 2004 Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 3 Tags Adjustment   - No  - No 1.91[0.54; 6.78]3639 -NADarcie - Isradipine, 2004 1   - Randomisation  - Randomisation 0.85[0.48; 1.49]17417527%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.99[0.56; 1.76]21021432%NADarcie - Isradipine, 2004 Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 3 All studiesAll studies 0.99[0.56; 1.76]21021432%NADarcie - Isradipine, 2004 Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.99[0.56; 1.76]21021432%NADarcie - Isradipine, 2004 Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 30.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period AbalosAbalos 0.94[0.79; 1.11]37%-unexposed, sickduring pregnancy (anytime or not specified)studies3 Alavifard (Nifedipine)Alavifard (Nifedipine) 1.06[0.47; 2.22]-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 Alavifard (Nifedipine)Alavifard (Nifedipine) 1.02[0.48; 2.04]-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 Bellos - AmlodipineBellos - Amlodipine 1.35[0.38; 4.80]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - AmlodipineBellos - Amlodipine 1.35[0.38; 4.80]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - NifedipineBellos - Nifedipine 0.85[0.56; 1.29]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bellos - NifedipineBellos - Nifedipine 0.85[0.56; 1.29]NA-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Firoz (Nifedipine)Firoz (Nifedipine) 0.85[0.56; 1.29]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies1 Firoz (Nifedipine)Firoz (Nifedipine) 1.23[0.76; 1.98]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies1 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (DUPLICATE) 1.02[0.77; 1.33]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies4 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION 1.02[0.77; 1.33]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies4 metaPregmetaPreg 0.99[0.56; 1.76]32%214--Darcie - Isradipine, 2004 Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 30.510.01.0